4.8 Article

Peptide nano 'bead-grafting' for SDT-facilitated immune checkpoints blocking

期刊

CHEMICAL SCIENCE
卷 13, 期 47, 页码 14052-14062

出版社

ROYAL SOC CHEMISTRY
DOI: 10.1039/d2sc02728c

关键词

-

资金

  1. National Natural Science Foundation of China
  2. Beijing Natural Science Foundation
  3. Beijing Institute of Technology Research Fund Program for Young Scholars
  4. [22074006]
  5. [2222029]

向作者/读者索取更多资源

This study presents a peptide-based nano 'bead-grafting' method for active delivery of quantum-dot nanoparticle drugs (NPDs). This approach combines immune checkpoint blockade (ICB) therapy with sonodynamic therapy (SDT) to effectively inhibit tumor growth and enhance the anti-tumor immune response. This research provides a new strategy for controlling and delivering NPDs with important implications for cancer treatment.
Combination therapies based on immune checkpoint blockade (ICB) are currently the mainstay of cancer treatment, in which the synergetic delivery of multiple drugs is the essential step. Although nanoparticle drugs (NPDs) show satisfactory anticancer effects, the promotion of active co-delivery of NPDs is premature, since the processes are usually difficult to predict and control. Targeting peptide self-assemblies have been widely used as carriers for small-molecular drugs, but remain elusive for NPDs. We describe here peptide-based nano 'bead-grafting' for the active delivery of quantum-dot NPDs through a co-assembly method. Based on a 'de novo' design, we used a 'one-bead-one-compound (OBOC)' combinatorial chemical screening method to select a peptide RT with high affinity for the immune checkpoint CD47, which could also form biocompatible nanofibers and efficiently trap Ag2S quantum dots along the self-assembly path. This system can combine ICB therapy and sonodynamic therapy (SDT) to effectively inhibit tumor growth. Moreover, the tumor antigen produced by SDT can activate the adaptive immune system, which enhances the anti-tumor immune response of the ICB and shows efficient inhibition of both primary and distant tumors. This study provides a new strategy for the active control and delivery of NPDs and a new option for ICB therapy with immune checkpoints that are highly susceptible to systemic side effects.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据